However, multiple preclinical study results indicate that LAG-3 and TIM-3 exhibit significantly high expression in ICC, and their expression levels are closely associated with patient clinical outcomes [40,73], which suggests that LAG-3 and TIM-3 may serve as novel potential targets for ICC immunotherapy, and the related ICIs and their therapeutic value warrant further in-depth investigation. The gene discussed is LAG3; the disease is intrahepatic cholangiocarcinoma.